What is Zacks Research’s Estimate for BDX Q3 Earnings?

Becton, Dickinson and Company (NYSE:BDX) – Equities researchers at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Becton, Dickinson and Company in a note issued to investors on Thursday, May 22nd. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $3.46 per share for the quarter, down from their prior forecast of $3.56. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $3.96 EPS, FY2025 earnings at $14.19 EPS, Q1 2026 earnings at $3.16 EPS, Q2 2026 earnings at $3.63 EPS, Q3 2026 earnings at $3.86 EPS, Q4 2026 earnings at $4.22 EPS, FY2026 earnings at $14.87 EPS, Q1 2027 earnings at $3.40 EPS, Q2 2027 earnings at $3.82 EPS and FY2027 earnings at $15.87 EPS.

Several other brokerages also recently issued reports on BDX. Piper Sandler downgraded shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. William Blair cut Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Thursday, May 1st. Bank of America cut Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target for the company. in a report on Thursday, May 1st. Barclays decreased their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating on the stock in a research note on Monday, April 7th. Finally, Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $221.44.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $171.49 on Friday. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average price is $198.36 and its 200 day moving average price is $218.80. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The stock has a market cap of $49.15 billion, a price-to-earnings ratio of 28.49, a PEG ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the prior year, the company earned $3.17 earnings per share. Becton, Dickinson and Company’s revenue was up 4.5% compared to the same quarter last year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.43%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s payout ratio is 79.39%.

Insider Activity

In related news, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the sale, the executive vice president now directly owns 6,952 shares in the company, valued at approximately $1,598,960. The trade was a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,878 shares of company stock valued at $636,393 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of institutional investors have recently added to or reduced their stakes in BDX. Wesbanco Bank Inc. grew its holdings in shares of Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 48 shares during the period. S.A. Mason LLC grew its stake in Becton, Dickinson and Company by 3.7% during the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock worth $321,000 after buying an additional 50 shares during the period. Hillsdale Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock worth $694,000 after acquiring an additional 50 shares in the last quarter. Northcape Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after acquiring an additional 51 shares during the period. Finally, Americana Partners LLC raised its stake in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after acquiring an additional 52 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.